A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)

NCT02265237 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

184

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus

Interventions

DRUG: ombitasvir/paritaprevir/ritonavir
DRUG: ribavirin

Sponsor

AbbVie